WuXi PharmaTech, a Chinese-headquartered pharmaceutical and biotechnology R&D outsourcing company has closed its initial public offering (IPO) of 15,167,326 American Depositary Shares ("ADSs"), including 1,978,347 ADSs issued in connection with the exercise of the over-allotment option in full.
WuXi PharmaTech's commenced trading on the New York Stock Exchange on 9 August 2007 under the symbol "WX". The US Securities and Exchange Commission (SEC) declared WuXi PharmaTech's registration statement effective.
Credit Suisse Securities (USA) and JP Morgan Securities acted as lead underwriters and joint book-runners and Jefferies & Company was co-manager in the offering.
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...